Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2011
|
| gptkbp:category |
targeted therapy
|
| gptkbp:combines |
gptkb:MEK_inhibitors
|
| gptkbp:contraindication |
wild-type BRAF tumors
|
| gptkbp:developedBy |
pharmaceutical companies
|
| gptkbp:hasApprovedDrug |
gptkb:encorafenib
gptkb:dabrafenib gptkb:sorafenib gptkb:vemurafenib |
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF inhibitors
|
| gptkbp:indication |
BRAF V600E mutation-positive cancers
|
| gptkbp:mechanismOfAction |
inhibit BRAF kinase activity
|
| gptkbp:resistantTo |
activation of alternative pathways
secondary mutations in BRAF |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:cutaneous_squamous_cell_carcinoma
fatigue rash photosensitivity arthralgia |
| gptkbp:target |
gptkb:BRAF_protein
|
| gptkbp:usedFor |
treatment of melanoma
treatment of non-small cell lung cancer treatment of anaplastic thyroid cancer |
| gptkbp:bfsParent |
gptkb:V600K
gptkb:BRAF_V600E gptkb:MEK_inhibitors |
| gptkbp:bfsLayer |
6
|